about
Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation.Invasive mold infections: recent advances in management approaches.Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.Anti-LFA-1 or rapamycin overcome costimulation blockade-resistant rejection in sensitized bone marrow recipients.
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Emerging therapies for graft-versus-host disease.
@ast
Emerging therapies for graft-versus-host disease.
@en
type
label
Emerging therapies for graft-versus-host disease.
@ast
Emerging therapies for graft-versus-host disease.
@en
prefLabel
Emerging therapies for graft-versus-host disease.
@ast
Emerging therapies for graft-versus-host disease.
@en
P2860
P356
P1476
Emerging therapies for graft-versus-host disease.
@en
P2093
David A Jacobsohn
P2860
P304
P356
10.1517/14728214.8.2.323
P407
P577
2003-11-01T00:00:00Z